Skanska awarded contract to build a cancer clinic in London

NewsGuard 100/100 Score

Skanska (STO:SKAB) has been awarded a contract to build a world-class cancer clinic in London for University College Hospitals NHS Foundation Trust. The contract amount is GBP 61 M, approximately SEK 740 M, which will be included in third-quarter order bookings.

The hospital building includes 14,800 square meters of floor space with five floors above and two floors below ground-floor level. The wards surround a central atrium.

Skanska will be responsible for the entire implementation of the project, from groundwork to building construction, including electrical and mechanical engineering installations and the renovation of existing tunnels.

On-site work will begin in September, and the hospital is scheduled for completion in October 2011.

Skanska aims to achieve environmental certification for the project in accordance with the British environmental certification standard BREEAM. The cancer centre will be one of the first in the UK to achieve Excellent rating under the new BREEAM 2008 Healthcare standard.

Skanska UK has about 4,800 employees and is active in building and civil construction, distribution networks and construction services. The Skanska Group reported revenues of SEK 17.9 billion in 2008. Skanska is also a leader in the Private Finance Initiative (PFI), a British program for public-private partnerships.

Skanska AB may be required to disclose the information provided herein pursuant to the Securities Markets Act.

http://www.skanska.com/

Posted in:

Tags: , ,

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
FDA-approved TIVDAK®: Targeting tissue factor in cervical cancer